AU2008354754B2 - On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors - Google Patents

On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors Download PDF

Info

Publication number
AU2008354754B2
AU2008354754B2 AU2008354754A AU2008354754A AU2008354754B2 AU 2008354754 B2 AU2008354754 B2 AU 2008354754B2 AU 2008354754 A AU2008354754 A AU 2008354754A AU 2008354754 A AU2008354754 A AU 2008354754A AU 2008354754 B2 AU2008354754 B2 AU 2008354754B2
Authority
AU
Australia
Prior art keywords
cancer
subject
chemotherapeutic agent
nucleotide analog
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008354754A
Other languages
English (en)
Other versions
AU2008354754A1 (en
Inventor
Manuel Medina Hidalgo
Antonio Jimeno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2008354754A1 publication Critical patent/AU2008354754A1/en
Application granted granted Critical
Publication of AU2008354754B2 publication Critical patent/AU2008354754B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008354754A 2008-04-17 2008-04-17 On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors Ceased AU2008354754B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/005104 WO2009128805A1 (en) 2008-04-17 2008-04-17 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors

Publications (2)

Publication Number Publication Date
AU2008354754A1 AU2008354754A1 (en) 2009-10-22
AU2008354754B2 true AU2008354754B2 (en) 2014-09-11

Family

ID=41199352

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008354754A Ceased AU2008354754B2 (en) 2008-04-17 2008-04-17 On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors

Country Status (10)

Country Link
US (2) US8962614B2 (enExample)
EP (1) EP2271339A4 (enExample)
JP (1) JP5479453B2 (enExample)
KR (1) KR101707669B1 (enExample)
CN (1) CN102056607B (enExample)
AU (1) AU2008354754B2 (enExample)
CA (1) CA2721722C (enExample)
NZ (1) NZ588749A (enExample)
RU (1) RU2476239C2 (enExample)
WO (1) WO2009128805A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721722C (en) * 2008-04-17 2015-12-08 The Johns Hopkins University On01910.na enhances chemotherapeutic agent activity in drug-resistant tumors
ES2864681T3 (es) * 2012-12-07 2021-10-14 Onconova Therapeutics Inc Tratamiento del cáncer hematológico refractario a un agente contra el cáncer
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
DK3138555T3 (da) 2014-04-30 2020-12-14 Fujifilm Corp Liposomsammensætning og fremgangsmåde til fremstilling heraf
WO2016137235A2 (ko) 2015-02-25 2016-09-01 (주)바이오니아 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물
US10669302B2 (en) * 2015-08-28 2020-06-02 Zhejianf Hisun Pharmaceutical Co., Ltd. Crystal form of fludarabine phosphate, preparation method therefor, and application thereof
CN109232403A (zh) * 2017-07-10 2019-01-18 亚宝药业集团股份有限公司 作为蛋白激酶抑制剂的酰胺类前药衍生物
JP7364561B2 (ja) * 2018-06-20 2023-10-18 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
TWI826738B (zh) * 2019-10-21 2023-12-21 奈威生技股份有限公司 癌症治療方法
WO2023158514A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
US20070203210A1 (en) * 2006-02-27 2007-08-30 John Frederick Boylan Thiazolyl-benzimidazoles
US20070265438A1 (en) * 2002-11-14 2007-11-15 Dharmacon, Inc. siRNA targeting polo-like kinase-1 (PLK-1)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321454A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070197538A1 (en) * 2004-10-07 2007-08-23 Mark Nesbit Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
US20090306207A1 (en) * 2005-01-05 2009-12-10 Reddy M V Ramana Treatment of Drug-Resistant Proliferative Disorders
WO2008027049A1 (en) * 2006-08-30 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
JP5528806B2 (ja) * 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US20080279874A1 (en) * 2007-05-07 2008-11-13 Wyeth Compositions and methods for modulation of plk1 kinase activity
CA2721722C (en) * 2008-04-17 2015-12-08 The Johns Hopkins University On01910.na enhances chemotherapeutic agent activity in drug-resistant tumors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20070265438A1 (en) * 2002-11-14 2007-11-15 Dharmacon, Inc. siRNA targeting polo-like kinase-1 (PLK-1)
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
US20070203210A1 (en) * 2006-02-27 2007-08-30 John Frederick Boylan Thiazolyl-benzimidazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUMIREDDY ET AL, CANCER CELL, V 7, P 275 MAR 2005 *

Also Published As

Publication number Publication date
CA2721722C (en) 2015-12-08
US20150209381A1 (en) 2015-07-30
JP5479453B2 (ja) 2014-04-23
EP2271339A4 (en) 2011-09-28
NZ588749A (en) 2012-06-29
KR101707669B1 (ko) 2017-02-16
CN102056607A (zh) 2011-05-11
JP2011518153A (ja) 2011-06-23
KR20100137570A (ko) 2010-12-30
US20110201675A1 (en) 2011-08-18
RU2476239C2 (ru) 2013-02-27
AU2008354754A1 (en) 2009-10-22
RU2010145048A (ru) 2012-05-27
EP2271339A1 (en) 2011-01-12
WO2009128805A1 (en) 2009-10-22
CA2721722A1 (en) 2009-10-22
CN102056607B (zh) 2014-07-30
US8962614B2 (en) 2015-02-24
US9545418B2 (en) 2017-01-17

Similar Documents

Publication Publication Date Title
AU2008354754B2 (en) On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
US12083136B2 (en) Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof
KR20180054793A (ko) 악성 간상소체 종양 또는 고칼슘혈증형 난소의 소세포 암을 치료하는 방법
JP7596323B2 (ja) ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法
TW201330845A (zh) 胰臟癌及／或膽道癌治療劑
EP3681503A1 (en) Protein kinase c inhibitors for treatment of uveal melanoma
JP2016503421A (ja) 薬剤耐性癌細胞の阻害
JP7696299B2 (ja) Ｇａｐｄｈを阻害する方法及び組成物
US11491168B2 (en) Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
ES2573295T3 (es) Combinaciones farmacéuticas que comprenden un inhibidor de Hsp90 derivado de isoxazol y el inhibidor de HER2 trastuzumab
ES2922752T3 (es) Composición combinada para prevenir o tratar el cáncer que comprende un derivado de benzofenona-tiazol como VDA y un inhibidor de topoisomerasa
US10434086B2 (en) Combination therapies with curaxins
TW202317128A (zh) 治療化療相關的胃腸道副作用的化合物和方法
CN118742325A (zh) 预防或治疗与抗肿瘤剂相关的疾病或病症的方法
HK1202419B (en) Combination therapy with a mitotic inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired